Bioclinica, Inc. (BIOC) Tops Q4 EPS by 2c, Sales Beat Expectations
Get Alerts BIOC Hot Sheet
Join SI Premium – FREE
Bioclinica, Inc. (NASDAQ: BIOC) reported Q4 EPS of $0.09, $0.02 better than the analyst estimate of $0.07. Revenue for the quarter came in at $22.57 million versus the consensus estimate of $20.84 million.
For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.
For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
- RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c
- Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share